Adenoviruses for better brain function
DOI:
https://doi.org/10.33910/2687-1270-2021-2-3-254-260Keywords:
adenovirus, vaccine, cancer, Parkinson’s disease, mechanismsAbstract
Using adenoviruses for therapy became well accepted due to some vaccines against COVID-19 pandemic. Actually, not the native viruses, but a recombinant form lacking fertility—a so called vector—is used with the aim to transfer genetic materials to adult cells. Decades of research preceded this development. Although the most important field of utilization is the vaccines, but neurological and even psychiatric disorders may also benefit from viral vectors. Neurons seem to be especially convenient target for viral vectors as they are considered as non-dividing cells. Extra genetic information provided by the viral vectors is not integrated into the genome rather remains in the cytoplasm as plasmid. During repeated cell divisions the cell loses this extra information, it is “diluted” and finally disappears. It is not the case in the slow dividing cells including neurons. For preclinical research purposes canine adenovirus 2 is widely used. It is a retrograde transporter therefore especially good in marking specific pathways between remote brain areas and providing a useful tool for functional brain mapping. Therapeutic usages include restoration of missing enzymes or parts of sensory systems and treatment of cancer. All in all, at present most of the studies on brain utilizing adenoviral vectors are still in preclinical phase and focus on studying mechanisms. However, we should be aware of this important topic, which may be an everyday therapy in the future.
References
Bienemann, A. S., Martin-Rendon, E., Cosgrave, A. S. et al. (2003) Long-term replacement of a mutated nonfunctional CNS gene: Reversal of hypothalamic diabetes insipidus using an EIAV-based lentiviral vector expressing arginine vasopressin. Molecular Therapy, vol. 7, no. 5, pp. 588–596. https://www.doi.org/10.1016/s1525-0016(03)00069-8 (In English)
Bru, T., Salinas, S., Kremer, E. J. (2010) An update on canine adenovirus type 2 and its vectors. Viruses, vol. 2, no. 9, pp. 2134–2153. https://www.doi.org/10.3390/v2092134 (In English)
Chen, W., Hu, Y., Ju, D. (2020) Gene therapy for neurodegenerative disorders: Advances, insights and prospects. Acta Pharmaceutica Sinica B, vol. 10, no. 8, pp. 1347–1359. https://www.doi.org/10.1016/j.apsb.2020.01.015 (In English)
Curtis, R., Jemmett, J. E., Furminger, I. G. (1978) The pathogenicity of an attenuated strain of canine adenovirus type 2 (CAV-2). Veterinary Record, vol. 103, no. 17, pp. 380–381. https://doi.org/10.1136/vr.103.17.380 (In English)
Daskalakis, N. P., Bagot, R. C., Parker, K. J. et al. (2013) The three-hit concept of vulnerability and resilience: Toward understanding adaptation to early-life adversity outcome. Psychoneuroendocrinology, vol. 38, no. 9, pp. 1858–1873. https://www.doi.org/10.1016/j.psyneuen.2013.06.008 (In English)
Del Rio, D., Beucher, B., Lavigne, M. et al. (2019) CAV-2 vector development and gene transfer in the central and peripheral nervous systems. Frontiers in Molecular Neuroscience, vol. 12, article 71. https://www.doi.org/10.3389/fnmol.2019.00071 (In English)
Engel, G. L. (1978) The biopsychosocial model and the education of health professionals. Annals of the New York Academy of Sciences, vol. 310, no. 1, pp. 169–187. https://www.doi.org/10.1111/j.1749-6632.1978.tb22070.x (In English)
From brain gene transfer towards gene therapy: Pharmacological assessment of AAV, CAV and LVV. (2016) CORDIS: Résultats de la recherche de l’UE. [Online]. Available at: https://cordis.europa.eu/project/id/286071/reporting/fr (accessed 25.06.2021). (In English)
Geddes, B. J., Harding, T. C., Lightman, S. L., Uney, J. B. (1997) Long-term gene therapy in the CNS: Reversal of hypothalamic diabetes insipidus in the Brattleboro rat by using an adenovirus expressing arginine vasopressin. Nature Medicine, vol. 3, no. 12, pp. 1402–1404. https://www.doi.org/10.1038/nm1297-1402 (In English)
Goldman, S. A., Nottebohm, F. (1983) Neuronal production, migration, and differentiation in a vocal control nucleus of the adult female canary brain. Proceedings of the National Academy of Sciences of the United States of America, vol. 80, no. 8, pp. 2390–2394. https://www.doi.org/10.1073/pnas.80.8.2390 (In English)
Huang, B.-J., Liu, R.-Y., Huang, J.-L. et al. (2007) Long-term toxicity studies in Canine of E10A, an adenoviral vector for human endostatin gene. Human Gene Therapy, vol. 18, no. 3, pp. 207–221. https://www.doi.org/10.1089/ hum.2006.149 (In English)
Ideno, J., Mizukami, H., Honda, K. et al. (2003) Persistent phenotypic correction of central diabetes insipidus using adeno-associated virus vector expressing arginine-vasopressin in Brattleboro rats. Molecular Therapy, vol. 8, no. 6, pp. 895–902. https://www.doi.org/10.1016/j.ymthe.2003.08.019 (In English)
Jooss, K., Chirmule, N. (2003) Immunity to adenovirus and adeno-associated viral vectors: Implications for gene therapy. Gene Therapy, vol. 10, no. 11, pp. 955–963. https://www.doi.org/10.1038/sj.gt.3302037 (In English)
Junyent, F., Kremer, E. J. (2015) CAV-2 — why a canine virus is a neurobiologist’s best friend. Current Opinion in Pharmacology, vol. 24, pp. 86–93. https://www.doi.org/10.1016/j.coph.2015.08.004 (In English)
Kumar, A., Pareek, V., Faiq, M. A. et al. (2019) Adult neurogenesis in humans: A review of basic concepts, history, current research, and clinical implications. Innovations in Clinical Neuroscience, vol. 16, no. 5-6, pp. 30–37. PMID: 31440399. (In English)
Lam, S., Cao, H., Wu, J. et al. (2014) Highly efficient retinal gene delivery with helper-dependent adenoviral vectors. Genes & Diseases, vol. 1, no. 2, pp. 227–237. https://www.doi.org/10.1016/j.gendis.2014.09.002 (In English)
Lee, C. S., Bishop, E. S., Zhang, R. et al. (2017) Adenovirus-mediated gene delivery: Potential applications for gene and cell-based therapies in the new era of personalized medicine. Genes & Diseases, vol. 4, no. 2, pp. 43–63. https://www.doi.org/10.1016/j.gendis.2017.04.001 (In English)
Li, C., Samulski, R. J. (2020) Engineering adeno-associated virus vectors for gene therapy. Nature Reviews Genetics, vol. 21, no. 4, pp. 255–272. https://www.doi.org/10.1038/s41576-019-0205-4 (In English)
Nottebohm, F. (1985) Neuronal replacement in adulthood. Annals of the New York Academy of Sciences, vol. 457, no. 1, pp. 143–161. https://www.doi.org/10.1111/j.1749-6632.1985.tb20803.x (In English)
Ord, E. N. J., Shirley, R., McClure, J. D. et al. (2013) Combined antiapoptotic and antioxidant approach to acute neuroprotection for stroke in hypertensive rats. Journal of Cerebral Blood Flow & Metabolism, vol. 33, no. 8, pp. 1215–1224. https://www.doi.org/10.1038/jcbfm.2013.70 (In English)
Planul, A., Dalkara, D. (2017) Vectors and gene delivery to the retina. Annual Review of Vision Science, vol. 3, pp. 121–140. https://www.doi.org/10.1146/annurev-vision-102016-061413 (In English)
Richardson, R. T., Atkinson, P. J. (2015) Atoh1 gene therapy in the cochlea for hair cell regeneration. Expert Opinion on Biological Therapy, vol. 15, no. 3, pp. 417–430. https://www.doi.org/10.1517/14712598.2015.1009889 (In English)
Safety, tolerability, and efficacy of intra labyrinthine (IL) CGF166 in patients with severe-to-profound hearing loss. (2019) ClinicalTrials.gov. [Online]. Available at: https://clinicaltrials.gov/ct2/show/NCT02132130 (accessed 25.06.2021). (In English)
Stephen, S. L., Montini, E., Sivanandam, V. G. et al. (2010) Chromosomal integration of adenoviral vector DNA in vivo. Journal of Virology, vol. 84, no. 19, pp. 9987–9994. https://www.doi.org/10.1128/JVI.00751-10 (In English)
Vecil, G. G., Lang, F. F. (2003) Clinical trials of adenoviruses in brain tumors: A review of Ad-p53 and oncolytic adenoviruses. Journal of Neuro-Oncology, vol. 65, no. 3, pp. 237–246. https://www.doi.org/10.1023/b:neon.0000003653.45635.32 (In English)
Yura, Y. (2017) Presage of oncolytic virotherapy for oral cancer with herpes simplex virus. Japanese Dental Science Review, vol. 53, no. 2, pp. 53–60. https://www.doi.org/10.1016/j.jdsr.2016.10.001 (In English)
Downloads
Published
Issue
Section
License
Copyright (c) 2021 Dora Zelena
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The work is provided under the terms of the Public Offer and of Creative Commons public license Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). This license allows an unlimited number of persons to reproduce and share the Licensed Material in all media and formats. Any use of the Licensed Material shall contain an identification of its Creator(s) and must be for non-commercial purposes only.
